Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AbbVie Inc

3 Safe Dividend Stocks to Buy in the Second Half of 2022

The market outlook seems dismal ahead of the Fed’s anticipated July rate hike announcement. Amid rising recession fears, more investors prefer dividend stocks for stable income assurance. Moreover, with dividend payouts slated to increase, we think it could be wise to invest in quality dividend stocks Nucor (NUE), The Procter…

StockNews.com

Ready to Retire? These 3 Stocks Could Help You Do It Earlier

Investors planning their retirement finances could benefit from investing in equities with stable return potential and consistent dividend payouts amid the current market volatility. On that front, investing in quality dividend-paying stocks Philip Morris (PM), Flowers Foods (FLO), and AbbVie (ABBV) could be rewarding. Read on….

StockNews.com

5 "Strong Buy" Pharmaceutical Stocks to Own for the Long Haul

The inelastic demand and rising investments in research and development should drive the pharmaceutical industry’s growth in the long run. Therefore, pharmaceutical stocks AbbVie (ABBV), Amgen (AMGN), Catalyst (CPRX), Novo Nordisk (NVO), and Vertex (VRTX), which possess sound fundamentals, could be solid long-term investments. These stocks are rated Strong Buy…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Dividend-Paying Healthcare Stocks to Outperform in the Bear Market

The bear market is creating a challenging environment for investors. One place to find outperformance could be high0-quality, healthcare stocks that are paying a dividend. Therefore, investors should consider dividend-paying healthcare stocks like Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Unitedhealth Group (UNH). .

StockNews.com

Why AbbVie Stock Is Trading Higher Today

AbbVie Inc (NYSE: ABBV) shares are trading higher Tuesday after the company announced it submitted a supplemental New Drug Application for atogepant to the U.S. Food and Drug Administration to support the preventive treatment of chronic migraine in adults.

Benzinga

Bargain-Hunting: 3 Mega-Cap Pharmaceutical Stocks to Buy and Hold

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

StockNews.com

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial

AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab. Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy. The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson-AbbVie Partnered Lymphoma Drug Slows Disease Progression, Data Shows

Johnson & Johnson (NYSE:JNJ) and AbbVie Inc (NYSE:ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL). The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR…

Benzinga

5 Stalwart Stocks to Load Up on During the Market Sell-Off

Worries about looming recession due to the Fed's tighter monetary policy and other macroeconomic headwinds have kept the stock market under pressure. Amid such a scenario, investing in shares of stalwart companies Intel (INTC), AbbVie (ABBV), FedEx(FDX)), Oracle (ORCL), and The Coca-Cola (KO) could help investors dodge the short-term market…

StockNews.com

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

AbbVie Inc (NYSE:ABBV) submitted its FDA marketing application for ABBV-951, a solution of levodopa and carbidopa prodrugs being evaluated in advanced Parkinson’s patients who don’t respond well to oral therapy. AbbVie’s theory here revolves around using a continuous, 24-hour infusion of its therapy. The levodopa and carbidopa prodrugs are delivered in small doses…

Benzinga

AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year

AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease. The trial included patients who had an inadequate response or were intolerant to conventional or biologic therapy. A significantly higher proportion of patients who received upadacitinib 15 mg or 30…

Benzinga

Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and AbbVie Inc's (NYSE:ABBV) Allergan Plc are willing to pay more than $5 billion combined to resolve more than 3,500 lawsuits filed over highly addictive opioid painkillers, according to three people familiar with settlement talks. The people said the companies have been in mediation talks with plaintiffs for more than a year. …

Benzinga

Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer

Myovant Sciences Ltd (NYSE:MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion product in advanced prostate cancer long term. But the surprise Myfembree setback in endometriosis has sparked uncertainty and new investor questions for Myovant's 2nd program. Hence, SVB remains on the…

Benzinga

AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters

San Francisco will start a trial against Walgreens Boots Alliance Inc (NASDAQ:WBA) and three other companies accused of fueling an opioid crisis in the city. San Francisco has alleged that Walgreens, Teva Pharmaceutical Industries Ltd (NYSE:TEVA), AbbVie Inc's (NYSE:ABBV) Allergan unit, and Teva-owned Anda Inc created a "public nuisance" by flooding the city with prescription opioids and failing…

Benzinga

JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters

Alabama reached $276 million in settlements with Johnson & Johnson (NYSE:JNJ), McKesson Corporation (NYSE:MCK), and Endo International Plc (NASDAQ:ENDP), resolving claims on the opioid addiction crisis, the state attorney general said. McKesson will pay $141 million. JNJ and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement. The three…

Benzinga

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)." The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs…

StockNews.com

After Rallying More Than 10% Year-to-Date, There's More in Store for These 3 Mega-Cap Stocks

Amid concerns over the Fed’s aggressive interest rate posture, the Russia-Ukraine war, and the emergence of a new COVID-19 variant, which are exacerbating supply chain constraints, the stock market is expected to remain volatile in the coming months. Thus, well-established mega-cap companies are attracting investors’ attention, given their ability to…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)

Benzinga

AbbVie Releases New Data From Mid-Stage Navitoclax Combo Trial In Bone Marrow Cancer

AbbVie Inc (NYSE: ABBV) has

StockNews.com

5 Global Healthcare Stocks to Buy as BofA Warns of a "Recession Shock"

The healthcare industry is well-positioned to ride out a potential recessionary shock, thanks in-part to the inelastic demand for COVID-19 vaccines worldwide. Thus, we think investors could invest in fundamentally sound healthcare stocks Pfizer Inc. (PFE), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Eli Lilly and Company (LLY), and Merck…

Benzinga

Allergan Shares Topline Data For Twice Daily Vuity (Pilocarpine) In Blurry Vision Study

Allergan, an AbbVie Inc (NYSE: ABBV) company, announced topline data from Phase 3 VIRGO trial evaluating Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia, age-related blurry near vision.

Benzinga

Rhode Island Announces $107M Opioid Settlements With Teva, Allergan: Reuters

Rhode Island's attorney general announced settlements worth $107 million against Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and AbbVie Inc's (NYSE: ABBV) Allergan unit to resolve claims over

Benzinga

FDA Clears AbbVie's Rinvoq For Moderate To Severe Active Ulcerative Colitis

The FDA approved AbbVie Inc's (NYSE:ABBV) Rinvoq (upadacitinib) for adults patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blockers. This FDA approval is the first indication for Rinvoq in gastroenterology and is supported by efficacy and safety data from…

Benzinga

AbbVie, Gedeon Richter Join Forces To Develop Dopamine Receptor Modulators For Neuropsychiatric Diseases

AbbVie Inc (NYSE: ABBV) and Gedeon Richter Plc have

1 … 3 4 5 6

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.